{"id":635348,"date":"2023-01-24T19:46:02","date_gmt":"2023-01-24T19:46:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=635348"},"modified":"2023-01-24T19:46:02","modified_gmt":"2023-01-24T19:46:02","slug":"diabetic-macular-edema-dme-market-to-observe-stupendous-growth-during-the-forecast-period-20192032-key-companies-novartis-beovu-4d-molecular-therapeutics-oculis-rezolute-rz402-oxurion","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/diabetic-macular-edema-dme-market-to-observe-stupendous-growth-during-the-forecast-period-20192032-key-companies-novartis-beovu-4d-molecular-therapeutics-oculis-rezolute-rz402-oxurion_635348.html","title":{"rendered":"Diabetic Macular Edema (DME) Market to Observe Stupendous Growth During the Forecast Period (2019-2032) | Key Companies – Novartis (Beovu), 4D Molecular Therapeutics, Oculis, Rezolute (RZ402), Oxurion"},"content":{"rendered":"
\n
\"Diabetic<\/a><\/div>\n
\n
Delveinsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n
The Diabetic Macular Edema (DME) Market size in the 7MM (i.e., the United States, EU4 (Germany, Spain, Italy, France), the UK and Japan) was found to be ~USD 2.9 billion in 2021.<\/div>\n

The Diabetic Macular Edema Market is anticipated to grow in the coming years owing to the growing awareness, improved management, and better outcomes with emerging therapies. Moreover, the increase in the diabetic population, a rise in the number of healthcare expenditures, and lifestyle changes are also anticipated to stimulate market growth in the coming years. <\/em><\/p>\n

DelveInsight’s “Diabetic Macular Edema Market Insights, Epidemiology, and Market Forecast 2032<\/strong>” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Diabetic Macular Edema market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).<\/p>\n

The Diabetic Macular Edema market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice\/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. <\/p>\n

 <\/p>\n

Diabetic Macular Edema: An Overview<\/strong><\/p>\n

Diabetic Macular Edema (DME) is triggered by diabetic retinopathy (DR), a well-known complication of diabetes. DR is the most prevalent diabetic eye disease and the leading cause of irreversible blindness in people in their working years in developed and other developing countries. Common signs and symptoms include dark spots like a smudge on glasses or gaps that may appear in the vision, blurred vision, double vision, colors can fade, or the affected person may find bright light or glare difficult.<\/p>\n

All people with Type 1 or Type 2 diabetes are at risk for DR and Diabetic Macular Edema. The risk of developing DR or DME increases significantly the longer a person has diabetes. The American Academy of Ophthalmology (AAO) estimates that nearly 80% of patients with Type 1 diabetes will have developed DR after living with diabetes for 15 years. There are 50% chance that patients with Type 2 diabetes will develop DR after living with diabetes for around 20 years.<\/p>\n

Diabetic Macular Edema Market Key Facts<\/strong><\/p>\n